Show simple item record

dc.contributor.authorEchecopar-Sabogal, Jose*
dc.contributor.authorD’Angelo-Piaggio, Lorenzo*
dc.contributor.authorChanamé-Baca, Diego M*
dc.contributor.authorUgarte-Gil, Cesar*
dc.date.accessioned2018-11-27T17:00:51Z
dc.date.available2018-11-27T17:00:51Z
dc.date.issued2018-04
dc.identifier.issn0956-4624
dc.identifier.issn1758-1052
dc.identifier.doi10.1177/0956462417732226
dc.identifier.urihttp://hdl.handle.net/10757/624660
dc.descriptionEl texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.en_US
dc.description.abstractThis systematic review and meta-analysis tries to determine whether there is an association between the use of protease inhibitors (PIs) and the incidence of diabetes mellitus (DM) and/or metabolic syndrome (MS) in HIV-infected patients. A systematic literature search was performed using MEDLINE/PubMed, CENTRAL, LILACS, and EMBASE. Included articles were observational studies published on or prior to November 2015 that met specific inclusion criteria. Pooled relative risks (RRs) and hazard ratios (HRs) were calculated. Nine articles met the inclusion criteria, describing 13,742 HIV patients. Use of PIs was associated with the development of MS (RR: 2.11; 95% CI 1.28–3.48; p-value 0.003). No association between the use of PIs and development of DM was found: the HR for the incidence of DM among patients using PIs was 1.23 (95% CI 0.66–2.30; p-value: 0.51) and the RR was 1.25 (95% CI 0.99–1.58; p-value 0.06). Use of PIs in HIV-infected patients is associated with an increased risk of MS. No evidence of an increased risk of DM was found. However, because MS is a precursor to DM, it is possible that studies with a longer follow-up duration are needed in order to detect an association between PI use and onset of DM.en_US
dc.description.sponsorshipFirst, we would like to thank our families for all their support. Second, we would like to thank the Universidad Peruana de Ciencias Aplicadas, the Health Sciences Department, and the School of Medicine for their support and for all the tools they have provided throughout this process. Finally, we want to thanks to Dr Gwenyth O. Lee and Dr Daniela E. Kirwan for their comments.en_US
dc.formatapplication/pdfen_US
dc.publisherSAGE Publications Ltden_US
dc.relation.urlhttp://journals.sagepub.com/doi/10.1177/0956462417732226en_US
dc.rightsinfo:eu-repo/semantics/restrictedAccessen_US
dc.subjectAntiretroviral therapyen_US
dc.subjectDiabetes mellitusen_US
dc.subjectHIVen_US
dc.subjectMetabolic syndromeen_US
dc.subjectProtease inhibitoren_US
dc.subjectHuman immunodeficiency virus proteinase inhibitoren_US
dc.titleAssociation between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysisen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.identifier.journalInternational Journal of STD and AIDSen_US
dc.description.peerreviewRevisión por pareses_PE
dc.contributor.emailldangelop@gmail.comes_PE
dc.source.journaltitleInternational Journal of STD & AIDS
dc.source.volume29
dc.source.issue5
dc.source.beginpage443
dc.source.endpage452
refterms.dateFOA2018-11-27T17:00:51Z


Files in this item

Thumbnail
Name:
10.11770956462417732226.pdf
Size:
536.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record